Keywords: AstraZeneca, Crestor, VOYAGER study, Cholesterol lowerer, Differentiating benefits, LDL-C
New study reinforces the differentiating benefits of AstraZeneca's Crestor
Article | 29 May 2012
Data presented yesterday at the 2012 European Atherosclerosis Society (EAS) Congress in Milan, Italy, from the VOYAGER study demonstrate the benefits ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
